cediranib

Cediranib is a once-daily, orally available small molecule that acts as a highly potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, specifically targeting VEGFR-1, VEGFR-2, and VEGFR-3. It also inhibits c-Kit and platelet-derived growth factor receptors alpha and beta (PDGFRα/β). By blocking these receptors, cediranib limits angiogenesis—the formation of new blood vessels—which is essential for tumor growth and metastasis. Developed by AstraZeneca as an anti-cancer agent, it has been investigated in multiple cancer types including ovarian cancer, glioblastoma, colorectal cancer, non-small cell lung cancer, renal cell carcinoma, breast cancer, soft tissue sarcoma, endometrial cancer, gastric cancer, gastrointestinal stromal tumors (GIST), peritoneal cancer and others. Cediranib received orphan drug status for ovarian cancer and glioblastoma but has not achieved regulatory approval; several development programs have been discontinued or withdrawn after failing to meet clinical endpoints[1][5][6][7].

Brand names

RecentinZemfirza

Other names

cediranib-maleate